Medikit (7749) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2025, rose 6.5% year-over-year to ¥18,466 million, with operating profit up 0.8% to ¥3,657 million and profit attributable to owners of parent up 3.8% to ¥2,236 million.

• Comprehensive income increased 7.2% year-over-year to ¥2,216 million for the nine-month period.

Financial highlights

• Gross profit for the nine months ended December 31, 2025, was ¥7,224 million, up from ¥6,764 million year-over-year.

• Ordinary profit increased 2.6% year-over-year to ¥3,796 million.

• Basic earnings per share for the nine months ended December 31, 2025, was ¥153.28, up from ¥145.97 year-over-year.

• Total assets as of December 31, 2025, were ¥51,947 million, with net assets at ¥45,605 million.

Outlook and guidance

• Full-year forecast for fiscal year ending March 31, 2026: net sales of ¥24,000 million (up 6.4% year-over-year), operating profit of ¥4,500 million (up 0.3%), ordinary profit of ¥4,592 million (down 1.4%), and profit attributable to owners of parent of ¥2,924 million (down 3.0%).

• Basic earnings per share for the full year is projected at ¥200.75.

• Annual dividend forecast is ¥100.00 per share, up from ¥90.00 in the previous fiscal year.